Fibroblast growth factor signaling in metabolic regulation

Frontiers in Endocrinology

Volumn 6, Issue JAN, 2016, Pages

  Nies, Vera J M ^a   Sancar, Gencer ^b   Liu, Weilin ^a   Van Zutphen, Tim ^a   Struik, Dicky ^a   Yu, Ruth T ^b   Atkins, Annette R ^b   Evans, Ronald M ^b   Jonker, Johan W ^a   Downes, Michael Robert ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

FGF signaling; FGF1; FGF19; FGF21; Fibroblast growth factors; Metabolic syndrome; Therapeutic potential

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; KLOTHO PROTEIN;

BROWN ADIPOSE TISSUE; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; METABOLIC REGULATION; MODULATION; NONHUMAN; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THERMOGENESIS; UPREGULATION; WHITE ADIPOSE TISSUE;

EID: 84962606933     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00193     Document Type: Review

References (153)

1. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev (2005) 16:107-37. doi:10.1016/j.cytogfr.2005.01.008
2. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 8:235-53. doi:10.1038/nrd2792
3. Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, et al. A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 485:391-4. doi:10.1038/nature10998
4. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest (2005) 115:1627-35. doi:10.1172/JCI23606
5. Tomlinson E, Fu L, John L, Hultgren B. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology (2002) 143:1741-7. doi:10.1210/endo.143.5.8850
6. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 113:561-8. doi:10.1172/JCI200419081
7. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab (2012) 16:693-705. doi:10.1016/j.cmet.2012.11.001
8. Ohta H, Itoh N. Roles of FGFs as adipokines in adipose tissue development, remodeling, and metabolism. Front Endocrinol (2014) 5:18. doi:10.3389/fendo.2014.00018
9. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 2:217-25. doi:10.1016/j.cmet.2005.09.001
10. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 5:415-25. doi:10.1016/j.cmet.2007.05.003
11. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (2011) 331:1621-4. doi:10.1126/science.1198363
12. Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology (2012) 153:69-80. doi:10.1210/en.2010-1262
13. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes (2009) 58:1532-8. doi:10.2337/db08-1775
14. Luo Y, McKeehan WL. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol (2013) 4:194. doi:10.3389/fendo.2013.00194
15. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab (2014) 26:22-9. doi:10.1016/j.tem.2014.10.002
16. Suh JM, Jonker JW, Ahmadian M, Goetz R, Lackey D, Osborn O, et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature (2014) 513:436-9. doi:10.1038/nature13540
17. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology (2004) 145:2594-603. doi:10.1210/en.2003-1671
18. Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, Luo Y, et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab (2013) 2:31-7. doi:10.1016/j.molmet.2012.08.007
19. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab (2014) 20:670-7. doi:10.1016/j.cmet.2014.07.012
20. Straub L, Wolfrum C. FGF21, energy expenditure and weight loss-how much brown fat do you need? Mol Metab (2015) 4:605-9. doi:10.1016/j.molmet.2015.06.008
21. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köter A, Sandusky GE, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes (2006) 55:2470-8. doi:10.2337/db05-1435
22. Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev (2011) 27:286-97. doi:10.1002/dmrr.1177
23. Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides (2007) 28:2382-6. doi:10.1016/j.peptides.2007.10.007
24. Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, et al. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest (2013) 123:4799-808. doi:10.1172/JCI70710
25. Hanai K, Oomura Y, Kai Y, Nishikawa K, Shimizu N, Morita H, et al. Central action of acidic fibroblast growth factor in feeding regulation. Am J Physiol (1989) 256:R217-23.
26. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem (2010) 285:5165-70. doi:10.1074/jbc.M109.068783
27. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One (2013) 8:e58575. doi:10.1371/journal.pone.0058575
28. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 18:333-40. doi:10.1016/j.cmet.2013.08.005
29. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 24:2050-64. doi:10.1210/me.2010-0142
30. Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene (2001) 271:171-82. doi:10.1016/S0378-1119(01)00518-2
31. Eswarakumar V, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 16:139-49. doi:10.1016/j.cytogfr.2005.01.001
32. Harmer NJ, Ilag LL, Mulloy B, Pellegrini L, Robinson CV, Blundell TL. Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. J Mol Biol (2004) 339:821-34. doi:10.1016/j.jmb.2004.04.031
33. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res (2010) 342:1-11. doi:10.1007/s00441-010-1024-2
34. Mori S, Wu C-Y, Yamaji S, Saegusa J, Shi B, Ma Z, et al. Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem (2008) 283:18066-75. doi:10.1074/jbc.M801213200
35. Rusnati M, Tanghetti E, Dell'Era P, Gualandris A, Presta M. Alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell (1997) 8:2449-61. doi:10.1091/mbc.8.12.2449
36. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 27:3417-28. doi:10.1128/MCB.02249-06
37. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 104:7432-7. doi:10.1073/pnas.0701600104
38. Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One (2012) 7:e33870. doi:10.1371/journal.pone.0033870
39. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 281:15694-700. doi:10.1074/jbc.M601252200
40. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev (2005) 16:233-47. doi:10.1016/j.cytogfr.2005.01.007
41. Peters KG, Marie J, Wilson E, Ives HE, Escobedo J, Del Rosario M, et al. Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature (1992) 358:678-81. doi:10.1038/358678a0
42. Kouhara H, Hadari Y, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell (1997) 89:693-702. doi:10.1016/S0092-8674(00)80252-4
43. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci (2008) 99:1319-25. doi:10.1111/j.1349-7006.2008.00840.x
44. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene (2000) 19:3309-20. doi:10.1038/sj.onc.1203650
45. Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-α represses β-klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology (2012) 153:4238-45. doi:10.1210/en.2012-1193
46. So WY, Cheng Q, Chen L, Evans-Molina C, Xu A, Lam KSL, et al. High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling. Diabetes (2013) 62:3751-9. doi:10.2337/db13-0645
47. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, et al. BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol (2008) 22:1006-14. doi:10.1210/me.2007-0313
48. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell (2012) 148:556-67. doi:10.1016/j.cell.2011.11.062
49. Martens K, Bottelbergs A, Baes M. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research. FEBS Lett (2010) 584:1054-8. doi:10.1016/j.febslet.2010.01.061
50. Bookout AL, de Groot MHM, Owen BM, Lee S, Gautron L, Lawrence HL, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med (2013) 19:1147-52. doi:10.1038/nm.3249
51. Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, Ogimoto K, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes (2010) 59:1817-24. doi:10.2337/db09-1878
52. Mejhert N, Galitzky J, Pettersson AT, Bambace C, Blomqvist L, Bouloumié A, et al. Mapping of the fibroblast growth factors in human white adipose tissue. J Clin Endocrinol Metab (2010) 95:2451-7. doi:10.1210/jc.2009-2049
53. Hutley L, Shurety W, Newell F, McGeary R, Pelton N, Grant J, et al. Fibroblast growth factor 1: a key regulator of human adipogenesis. Diabetes (2004) 53:3097-106. doi:10.2337/diabetes.53.12.3097
54. Newell FS, Su H, Tornqvist H, Whitehead JP, Prins JB, Hutley LJ. Characterization of the transcriptional and functional effects of fibroblast growth factor-1 on human preadipocyte differentiation. FASEB J (2006) 20:2615-7. doi:10.1096/fj.05-5710fje
55. Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol (2008) 15:215-20. doi:10.1097/MOH.0b013e3282f97d98
56. Wu X, Ge H, Lemon B, Weiszmann J, Gupte J, Hawkins N, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci U S A (2009) 106:14379-84. doi:10.1073/pnas.0907812106
57. Adams AC, Coskun T, Rovira ARI, Schneider MA, Raches DW, Micanovic R, et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One (2012) 7:e38438. doi:10.1371/journal.pone.0038438
58. Wu A-L, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One (2011) 6:e17868. doi:10.1371/journal.pone.0017868
59. Yang C, Wang C, Ye M, Jin C, He W, Wang F, et al. Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress. Nutr Metab (Lond) (2012) 9:94. doi:10.1186/1743-7075-9-94
60. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology (2008) 149:6018-27. doi:10.1210/en.2008-0816
61. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab (2013) 17:790-7. doi:10.1016/j.cmet.2013.03.019
62. Lin Z, Tian H, Lam KSL, Lin S, Hoo RCL, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab (2013) 17:779-89. doi:10.1016/j.cmet.2013.04.005
63. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, et al. ßKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab (2012) 16:387-93. doi:10.1016/j.cmet.2012.08.002
64. Adams AC, Cheng CC, Coskun T, Kharitonenkov A. FGF21 requires ßklotho to act in vivo. PLoS One (2012) 7:e49977. doi:10.1371/journal.pone.0049977
65. Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, Arumugam M, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest (2014) 124:515-27. doi:10.1172/JCI67353
66. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARγ signaling. J Cell Physiol (2007) 6:1-6. doi:10.1002/jcp.20847
67. Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, et al. Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One (2013) 8:e73011. doi:10.1371/journal.pone.0073011
68. Ge X, Chen C, Hui X, Wang Y, Lam KSL, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem (2011) 286:34533-41. doi:10.1074/jbc.M111.248591
69. Chau MDL, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A (2010) 107:12553-8. doi:10.1073/pnas.1006962107
70. Betz MJ, Enerbäck S. Therapeutic prospects of metabolically active brown adipose tissue in humans. Front Endocrinol (2011) 2:86. doi:10.3389/fendo.2011.00086
71. Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med (2011) 17:736-40. doi:10.2119/molmed.2011.00075
72. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1a and browning of white adipose tissues in adaptive thermogenesis. Genes Dev (2012) 26:271-81. doi:10.1101/gad.177857.111
73. Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 286:12983-90. doi:10.1074/jbc.M110.215889
74. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 11:206-12. doi:10.1016/j.cmet.2010.02.001
75. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes (2009) 58:250-9. doi:10.2337/db08-0392
76. Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology (2014) 146:539-49.e7. doi:10.1053/j.gastro.2013.10.059
77. Cousin B, Cinti S, Morroni M, Raimbault S, Ricquier D, Pénicaud L, et al. Occurrence of brown adipocytes in rat white adipose tissue: molecular and morphological characterization. J Cell Sci (1992) 103(Pt 4):931-42.
78. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes (2014) 63:4057-63. doi:10.2337/db14-0595
79. Camporez JPG, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology (2013) 154:3099-109. doi:10.1210/en.2013-1191
80. Bernardo B, Lu M, Bandyopadhyay G, Li P, Zhou Y, Huang J, et al. FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance. Sci Rep (2015) 5:11382. doi:10.1038/srep11382
81. Véniant MM, Sivits G, Helmering J, Komorowski R, Lee J, Fan W, et al. Pharmacologic effects of FGF21 are independent of the "browning" of white adipose tissue. Cell Metab (2015) 21:731-8. doi:10.1016/j.cmet.2015.04.019
82. Samms RJ, Smith DP, Cheng CC, Antonellis PP, Perfield JW 2nd, Kharitonenkov A, et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep (2015) 11:991-9. doi:10.1016/j.celrep.2015.04.046
83. Kwon MM, O'Dwyer SM, Baker RK, Covey SD, Kieffer TJ. FGF21-mediated improvements in glucose clearance require uncoupling protein 1. Cell Rep (2015) 13:1521-7. doi:10.1016/j.celrep.2015.10.021
84. Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T, et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev (2000) 98:115-9. doi:10.1016/S0925-4773(00)00439-1
85. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require klotho beta. J Biol Chem (2007) 282:27277-84. doi:10.1074/jbc.M704244200
86. Yu C. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem (2000) 275:15482-9. doi:10.1074/jbc.275.20.15482
87. Kuipers F, Groen AK. FXR: the key to benefits in bariatric surgery? Nat Med (2014) 20:337-8. doi:10.1038/nm.3525
88. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev (2003) 17:1581-91. doi:10.1101/gad.1083503
89. Kong B, Wang L, Chiang JYL, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology (2012) 56:1034-43. doi:10.1002/hep.25740
90. Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes (2007) 56:2501-10. doi:10.2337/db07-0648
91. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab (2008) 8:224-36. doi:10.1016/j.cmet.2008.07.007
92. Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep (2009) 9:208-14. doi:10.1007/s11892-009-0034-5
93. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol (2012) 32:1220-7. doi:10.1161/ATVBAHA.111.243055
94. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 160:2295-307. doi:10.1016/S0002-9440(10)61177-7
95. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med (2015) 21:159-65. doi:10.1038/nm.3760
96. Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology (2011) 152:2996-3004. doi:10.1210/en.2011-0281
97. Schwartz MW, Porte D. Diabetes, obesity, and the brain. Science (2005) 307:375-9. doi:10.1126/science.1104344
98. Schwartz MW, Seeley RJ, Tschöp MH, Woods SC, Morton GJ, Myers MG, et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature (2013) 503:59-66. doi:10.1038/nature12709
99. Oomura Y, Sasaki K, Suzuki K, Muto T, Li AJ, Ogita Z, et al. A new brain glucosensor and its physiological significance. Am J Clin Nutr (1992) 55:278S-82S.
100. Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology (2013) 154:9-15. doi:10.1210/en.2012-1891
101. Deguchi Y, Naito T, Yuge T, Furukawa A, Yamada S, Pardridge WM, et al. Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. Pharm Res (2000) 17:63-9. doi:10.1023/A:1007570509232
102. Hsuchou H, Pan W, Kastin AJ. Fibroblast growth factor 19 entry into brain. Fluids Barriers CNS (2013) 10:32. doi:10.1186/2045-8118-10-32
103. Sasaki K, Li A-J, Oomura Y, Muto T, Hanai K, Tooyama I, et al. Effects of fibroblast growth factors and related peptides on food intake by rats. Physiol Behav (1994) 56:211-8. doi:10.1016/0031-9384(94)90186-4
104. Sasaki K, Oomura Y, Suzuki K, Muto T, Hanai K, Tooyama I, et al. Effects of fibroblast growth factors and platelet-derived growth factor on food intake in rats. Brain Res Bull (1991) 27:327-32. doi:10.1016/0361-9230(91)90120-9
105. Li AJ, Oomura Y, Hori T, Aou S, Sasaki K, Kimura H, et al. Fibroblast growth factor receptor-1 in the lateral hypothalamic area regulates food intake. Exp Neurol (1996) 137:318-23. doi:10.1006/exnr.1996.0032
106. Sasaki K, Oomura Y, Li AJ, Hanai K, Tooyama I, Kimura H, et al. Actions of acidic fibroblast growth factor fragments on food intake in rats. Obes Res (1995) 3(Suppl 5):697S-706S. doi:10.1002/j.1550-8528.1995.tb00488.x
107. Suzuki S, Li AJ, Ishisaki A, Hou X, Hasegawa M, Fukumura M, et al. Feeding suppression by fibroblast growth factor-1 is accompanied by selective induction of heat shock protein 27 in hypothalamic astrocytes. Eur J Neurosci (2001) 13:2299-308. doi:10.1046/j.0953-816x.2001.01606.x
108. De Saint Hilaire Z, Nicolaïdis S. Enhancement of slow wave sleep parallel to the satiating effect of acidic fibroblast growth factor in rats. Brain Res Bull (1992) 29:525-8. doi:10.1016/0361-9230(92)90094-E
109. Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Commun (2015) 6:6980. doi:10.1038/ncomms7980
110. Patel R, Bookout AL, Magomedova L, Owen BM, Consiglio GP, Shimizu M, et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol Endocrinol (2015) 29:213-23. doi:10.1210/me.2014-1259
111. Rothwell NJ. Central effects of CRF on metabolism and energy balance. Neurosci Biobehav Rev (1990) 14:263-71. doi:10.1016/S0149-7634(05)80037-5
112. Miralles F, Czernichow P, Ozaki K, Itoh N, Scharfmann R. Signaling through fibroblast growth factor receptor 2b plays a key role in the development of the exocrine pancreas. Proc Natl Acad Sci U S A (1999) 96:6267-72. doi:10.1073/pnas.96.11.6267
113. Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature (2000) 408:864-8. doi:10.1038/35048589
114. Dichmann DS, Miller CP, Jensen J, Scott Heller R, Serup P. Expression and misexpression of members of the FGF and TGFbeta families of growth factors in the developing mouse pancreas. Dev Dyn (2003) 226:663-74. doi:10.1002/dvdy.10270
115. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes (2002) 51(Suppl 3):S405-13. doi:10.2337/diabetes.51.2007.S405
116. Sun MY, Yoo E, Green BJ, Altamentova SM, Kilkenny DM, Rocheleau JV. Autofluorescence imaging of living pancreatic islets reveals fibroblast growth factor-21 (FGF21)-induced metabolism. Biophys J (2012) 103:2379-88. doi:10.1016/j.bpj.2012.10.028
117. Kim I, Moon S-O, Yu K-H, Kim U-H, Koh GY. A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas. Biochim Biophys Acta (2001) 1518:152-6. doi:10.1016/S0167-4781(00)00282-7
118. Silva PN, Altamentova SM, Kilkenny DM, Rocheleau JV. Fibroblast growth factor receptor like-1 (FGFRL1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation. J Biol Chem (2013) 288:17859-70. doi:10.1074/jbc.M112.440677
119. Floss T, Arnold HH, Braun T. A role for FGF-6 in skeletal muscle regeneration. Genes Dev (1997) 11:2040-51. doi:10.1101/gad.11.16.2040
120. Zhao P, Hoffman EP. Embryonic myogenesis pathways in muscle regeneration. Dev Dyn (2004) 229:380-92. doi:10.1002/dvdy.10457
121. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology (2009) 150:4084-93. doi:10.1210/en.2009-0221
122. Lee MS, Choi S-E, Ha ES, An S-Y, Kim TH, Han SJ, et al. Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-κB. Metabolism (2012) 61:1142-51. doi:10.1016/j.metabol.2012.01.012
123. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett (2008) 582:3805-10. doi:10.1016/j.febslet.2008.10.021
124. Cuevas-Ramos D, Almeda-Valdés P, Meza-Arana CE, Brito-Córdova G, Gómez-Pérez FJ, Mehta R, et al. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One (2012) 7:e38022. doi:10.1371/journal.pone.0038022
125. Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T, et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes (2009) 58:2797-801. doi:10.2337/db09-0713
126. Tyynismaa H, Carroll CJ, Raimundo N, Ahola-Erkkilä S, Wenz T, Ruhanen H, et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet (2010) 19:3948-58. doi:10.1093/hmg/ddq310
127. Suomalainen A, Elo JM, Pietiläinen KH, Hakonen AH, Sevastianova K, Korpela M, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol (2011) 10:806-18. doi:10.1016/S1474-4422(11)70155-7
128. Lindegaard B, Hvid T, Grøndahl T, Frosig C, Gerstoft J, Hojman P, et al. Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV. PLoS One (2013) 8:e55632. doi:10.1371/journal.pone.0055632
129. Crooks DR, Natarajan TG, Jeong SY, Chen C, Park SY, Huang H, et al. Elevated FGF21 secretion, PGC-1a and ketogenic enzyme expression are hallmarks of iron-sulfur cluster depletion in human skeletal muscle. Hum Mol Genet (2014) 23:24-39. doi:10.1093/hmg/ddt393
130. Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol (2013) 4:247. doi:10.3389/fphys.2013.00247
131. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun (2013) 4:2019. doi:10.1038/ncomms3019
132. Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A (2012) 109:3143-8. doi:10.1073/pnas.1200797109
133. Xia X, Babcock JP, Blaber SI, Harper KM, Blaber M. Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application. PLoS One (2012) 7:e48210. doi:10.1371/journal.pone.0048210
134. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors?: first clinical results of a new treatment of coronary heart disease. Circulation (1998) 97:645-50. doi:10.1161/01.CIR.97.7.645
135. Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem (1975) 250:2515-20.
136. Imamura T, Engleka K, Zhan X, Tokita Y, Forough R, Roeder D, et al. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science (1990) 249:1567-70. doi:10.1126/science.1699274
137. Yamaji S, Saegusa J, Ieguchi K, Fujita M, Mori S, Takada YK, et al. A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist. PLoS One (2010) 5:e10273. doi:10.1371/journal.pone.0010273
138. Mori S, Tran V, Nishikawa K, Kaneda T, Hamada Y, Kawaguchi N, et al. A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. PLoS One (2013) 8:e57927. doi:10.1371/journal.pone.0057927
139. Wu X, Ge H, Lemon B, Vonderfecht S, Baribault H, Weiszmann J, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A (2010) 107:14158-63. doi:10.1073/pnas.1009427107
140. Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N, et al. FGF21 N-and C-termini play different roles in receptor interaction and activation. FEBS Lett (2009) 583:19-24. doi:10.1016/j.febslet.2008.11.023
141. Hecht R, Li Y-S, Sun J, Belouski E, Hall M, Hager T, et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One (2012) 7:e49345. doi:10.1371/journal.pone.0049345
142. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, et al. Different roles of N-and C-termini in the functional activity of FGF21. J Cell Physiol (2009) 219:227-34. doi:10.1002/jcp.21675
143. Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Mol Metab (2014) 3:221-9. doi:10.1016/j.molmet.2013.12.003
144. Gimeno RE, Moller DE. FGF21-based pharmacotherapy-potential utility for metabolic disorders. Trends Endocrinol Metab (2014) 25:303-11. doi:10.1016/j.tem.2014.03.001
145. Xu J, Bussiere J, Yie J, Sickmier A, An P, Belouski E, et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug Chem (2013) 24:915-25. doi:10.1021/bc300603k
146. Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther (2013) 346:270-80. doi:10.1124/jpet.113.204420
147. Ho HK, Yeo AHL, Kang TS, Chua BT. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discov Today (2014) 19:51-62. doi:10.1016/j.drudis.2013.07.021
148. Sun HD, Malabunga M, Tonra JR, DiRenzo R, Carrick FE, Zheng H, et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab (2007) 292:E964-76. doi:10.1152/ajpendo.00089.2006
149. Wu A-L, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 3:113ra126. doi:10.1126/scitranslmed.3002669
150. Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the ßKlotho/FGFR1c receptor complex. Sci Transl Med (2012) 4:162ra153. doi:10.1126/scitranslmed.3004690
151. Smith R, Duguay A, Bakker A, Li P, Weiszmann J, Thomas MR, et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-klotho bispecific protein. PLoS One (2013) 8:e61432. doi:10.1371/journal.pone.0061432
152. Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, et al. Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1/ßKlotho complex. EBioMedicine (2015) 2:730-43. doi:10.1016/j.ebiom.2015.05.028
153. Lelliott CJ, Ahnmark A, Admyre T, Ahlstedt I, Irving L, Keyes F, et al. Monoclonal antibody targeting of fibroblast growth factor receptor 1c ameliorates obesity and glucose intolerance via central mechanisms. PLoS One (2014) 9:e112109. doi:10.1371/journal.pone.0112109